CLINICAL TRIALS PROFILE FOR ISTRADEFYLLINE
✉ Email this page to a colleague
All Clinical Trials for istradefylline
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00199355 ↗ | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa | Completed | Kyowa Hakko Kirin Company, Limited | Phase 2 | 2005-04-01 | To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa. |
NCT00199355 ↗ | A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa | Completed | Kyowa Kirin Co., Ltd. | Phase 2 | 2005-04-01 | To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa. |
NCT00199368 ↗ | An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 | Completed | Kyowa Hakko Kirin UK, Ltd. | Phase 3 | 2004-10-01 | This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018. |
NCT00199368 ↗ | An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 | Completed | Kyowa Kirin Pharmaceutical Development, Inc. | Phase 3 | 2004-10-01 | This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018. |
NCT00199368 ↗ | An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018 | Completed | Kyowa Kirin, Inc. | Phase 3 | 2004-10-01 | This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018. |
NCT00199381 ↗ | An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001 | Terminated | Kyowa Kirin Pharmaceutical Development, Inc. | Phase 3 | 2005-10-01 | This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for istradefylline
Condition Name
Clinical Trial Locations for istradefylline
Trials by Country
Clinical Trial Progress for istradefylline
Clinical Trial Phase
Clinical Trial Sponsors for istradefylline
Sponsor Name